MONTVALE, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI) today announced that a Letter to Stockholders is now posted to the Company's Web site http://www.synvista.com. The text is as follows:
To Our Stockholders:
The team at Synvista Therapeutics has made tremendous progress in our
efforts to deliver on the promise of personalized medicine, and to redefine
the treatment of cardiovascular disease in diabetics as well as the
treatment of other diseases in the general population. Since my last letter
in August 2007, our clinical trials with SYI-2074 for the treatment of
heart disease in diabetics had inconclusive results, and we opted not to
move forward with the compound's development in this indication. However,
we have a robust pipeline on which we are building our business. We have:
-- Advanced our Haptoglobin (Hp) diagnostic test.
-- Developed a test for Carboxy-methyl-lysine (CML), a biomarker of
advanced glycation end product (A.G.E.) formation, which is believed to
play a part in cardiovascular disease.
-- Initiated two Phase 2 trials with alagebrium for chronic heart failure.
-- Advanced the development of a topical formulation for the use of
SYI-2074 in the treatment of psoriasis.
-- Chosen a lead Glutathione peroxidase mimetic generated in a discovery
collaboration with Provid Pharmaceuticals, that is now being evaluated
for its ability to restore reverse cholesterol transport and treat
-- Strengthened our management team and board of directors with
appointments in research, development and marketin
|SOURCE Synvista Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved